The NIH starts spending $1.5 billion in new Brain Research through Advancing Innovative Neuro-technologies (BRAIN) projects

By SharpBrains | March 7, 2018

___ NIH Starts to Spend $4.8 Bil­lion in “Extra” Cures Drug Research Mon­ey (P&T Com­mu­ni­ty): “The Nation­al Insti­tutes of Health (NIH) launched 110 new brain research projects in the fis­cal year end­ing last Sep­tem­ber (2017) with the first por­tion of the $1.5 bil­lion over 10 years it will hope­ful­ly receive from the 21st Cen­tu­ry Cures…

Read More

With pharma exiting Alzheimer’s research, new hope (and urgency) seen in the combination of brain training and transcranial direct current stimulation (tDCS)

By SharpBrains | January 22, 2018

___ What does the future hold for the war on Alzheimer’s? (The Globe and Mail): “After spend­ing huge sums on clin­i­cal trails in recent years, the phar­ma­ceu­ti­cal indus­try has failed to find a drug that can halt the mind-rob­bing dis­ease. And this month, Pfiz­er announced it is end­ing its Alzheimer’s research, although oth­er com­pa­nies haven’t thrown…

Read More

Akili raises an additional $11.9M; brings Amgen, Merck, Pfizer and Shire to the digital medicine table

By SharpBrains | July 21, 2016

—– Akili Adds Amgen Ven­tures and M Ven­tures* to Series B Financ­ing, Increas­ing Round to $42.4 Mil­lion (press release): “Akili Inter­ac­tive Labs, Inc. (“Akili”), a dig­i­tal med­i­cine com­pa­ny devel­op­ing nov­el, non-phar­­ma­­co­log­i­­cal ther­a­peu­tics and diag­nos­tics for cog­ni­tive dis­or­ders, today announced an $11.9 mil­lion expan­sion of its recent Series B financing. 

Read More

Brain Training and Cognitive Assessment Market Surpassed $1.3 Billion In 2013

By SharpBrains | January 23, 2014

Heads-up: We just announced a new intel­li­gence pack­age aimed at edu­ca­tion, health, gam­ing and tech­nol­o­gy exec­u­tives and inno­va­tors. “Many mar­ket reports pro­vide lit­tle val­ue for the mon­ey. This mar­ket report by Sharp­Brains is the pre­cise oppo­site. Its wealth of data and analy­sis pro­vides very valu­able strate­gic and busi­ness devel­op­ment guid­ance to orga­ni­za­tions at the frontier…

Read More

CEO of Cambridge Cognition to speak at 2013 SharpBrains Summit

By SharpBrains | June 14, 2013

Ruth Frances Keir runs Cam­bridge Cog­ni­tion (AIM: COG), one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, which devel­ops and com­mer­cial­izes com­put­erised neu­ropsy­cho­log­i­cal tests used in a vari­ety of health­care and research set­tings. She joined the Cam­bridge Cog­ni­tion board ini­tial­ly in 2010 as a non-exec­u­­tive direc­tor, bring­ing to it more…

Read More